Half of inflammatory myofibroblastic tumors (IMTs) regardless of anatomic location harbor anaplastic lymphoma kinase gene (ALK) rearrangements and overexpress anaplastic lymphoma kinase protein. The wide application of next-generation sequencing and the clinical benefit to tyrosine kinase inhibitors have opened new opportunities for investigation of ALK-negative IMTs.
Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements / Chang, J.C., Zhang, L., Drilon, A.E., Chi, P., Alaggio, R., Borsu, L., Benayed, R., Travis, W.D., Ladanyi, M., Antonescu, C.R.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 14:5(2019), pp. 825-834. [10.1016/j.jtho.2018.12.003]
Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements
Alaggio, Rita;
2019
Abstract
Half of inflammatory myofibroblastic tumors (IMTs) regardless of anatomic location harbor anaplastic lymphoma kinase gene (ALK) rearrangements and overexpress anaplastic lymphoma kinase protein. The wide application of next-generation sequencing and the clinical benefit to tyrosine kinase inhibitors have opened new opportunities for investigation of ALK-negative IMTs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Chang_Expanding_2019.pdf
accesso aperto
Note: https://www.sciencedirect.com/science/article/pii/S1556086418335123
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.57 MB
Formato
Adobe PDF
|
1.57 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
